|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- Xolair (omalizumab) / Roche, Novartis
New P1 trial: OXAD: Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Aug 30, 2012
P1, N=8, Completed, Sponsor: Stanford University
- Clinical: A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis (clinicaltrials.gov) - Aug 27, 2012
P=N/A, N=100, Recruiting, Sponsor: Yale University
- | SB-705498 / GSK
New P1 trial: Investigation of Topical SB705498 on Healthy Volunteers (clinicaltrials.gov) - Aug 26, 2012
P1, N=16, Completed, Sponsor: GlaxoSmithKline
- ||| BMS-981164 / BMS
Enrollment open: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Aug 22, 2012
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting
- ||| montelukast / Generic mfg.
Trial completion: The Effectiveness of Montelukast on Atopic Dermatitis in Koreans (clinicaltrials.gov) - Aug 14, 2012
P=N/A, N=54, Completed, Sponsor: Pyun BokYang
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- | New P4 trial: Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet (clinicaltrials.gov) - Aug 12, 2012
P4, N=80, Completed, Sponsor: The Korean Society of Ginseng
- Enrollment change: Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=31, Completed, Sponsor: Wake Forest School of Medicine
Not yet recruiting --> Completed N=15 --> 31
- Enrollment change: Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=45, Completed, Sponsor: Wake Forest School of Medicine
N=15 --> 31 N=30 --> 45
- Trial completion: Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=31, Completed, Sponsor: Wake Forest School of Medicine
N=30 --> 45 Recruiting --> Completed
- Trial completion: Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=45, Completed, Sponsor: Wake Forest School of Medicine
Recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management (clinicaltrials.gov) - Aug 6, 2012
P=N/A, N=37, Completed, Sponsor: Dermatology & Aesthetics of Wicker Park
- Clinical: Use of 2-octyl-cyanoacrylate Together With a Self-adhering Mesh (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=2, Completed, Sponsor: Medical University of Graz
- | Eucrisa (crisaborole) / Pfizer
New P1/2 trial: Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis (clinicaltrials.gov) - Jul 26, 2012
P1/2, N=23, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
- |||| mapracorat (BOL-303242-X) / Bayer
Trial completion: Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD) (clinicaltrials.gov) - Jul 22, 2012
P2, N=197, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| mapracorat (BOL-303242-X) / Bayer
Trial completion: Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD) (clinicaltrials.gov) - Jul 18, 2012
P2, N=263, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | mapracorat (BOL-303242-X) / Bayer
Enrollment change: HPA Axis Study in Japanese Adults (clinicaltrials.gov) - Jul 18, 2012
P2, N=12, Completed, Sponsor: Bayer
Active, not recruiting --> Completed N=10 --> 12
- | mapracorat (BOL-303242-X) / Bayer
Trial completion: HPA Axis Study in Japanese Adults (clinicaltrials.gov) - Jul 18, 2012
P2, N=12, Completed, Sponsor: Bayer
N=10 --> 12 Active, not recruiting --> Completed
- || Enrollment closed: Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) (clinicaltrials.gov) - Jul 13, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: Genetic Disease Investigators
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Dupixent (dupilumab) / Sanofi, Regeneron
New P2 trial: Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) (clinicaltrials.gov) - Jul 10, 2012
P2, N=31, Completed, Sponsor: Regeneron Pharmaceuticals
- Clinical: Effectiveness of Melatonin for Sleep Disturbances in Children With Atopic Dermatitis (clinicaltrials.gov) - Jul 9, 2012
P=N/A, N=40, Recruiting, Sponsor: National Taiwan University Hospital
- Filsuvez (AP101) / Amryt
Trial completion: Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10) (clinicaltrials.gov) - Jul 9, 2012
P2, N=10, Completed, Sponsor: Birken AG
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Edsivo (celiprolol) / Acer Therap
Enrollment change: Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type (clinicaltrials.gov) - Jul 3, 2012
P4, N=54, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed N=100 --> 54
- Trial completion, HEOR, Cost effectiveness: OnderHUIDs: Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - Jul 3, 2012
P4, N=50, Completed, Sponsor: University Hospital, Ghent
N=100 --> 54 Active, not recruiting --> Completed
- Review, Enrollment change: Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=11, Completed, Sponsor: Edimer Pharmaceuticals
Active, not recruiting --> Completed N=50 --> 11
- Enrollment change: Sweat Duct Imaging in Mother/Newborn Dyads (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=28, Completed, Sponsor: Edimer Pharmaceuticals
N=50 --> 11 N=40 --> 28
- Enrollment change: Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=27, Completed, Sponsor: Edimer Pharmaceuticals
N=40 --> 28 N=40 --> 27
- Clinical: Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012) (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=30, Completed, Sponsor: Edimer Pharmaceuticals
- ||| Trial completion: Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=64, Completed, Sponsor: Edimer Pharmaceuticals
N=40 --> 27 Recruiting --> Completed
- | Trial completion: Sweat Duct Imaging in Mother/Newborn Dyads (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=28, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=27, Completed, Sponsor: Edimer Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis (clinicaltrials.gov) - Jun 17, 2012
P2, N=183, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed N=140 --> 183
- Trial completion: Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis (clinicaltrials.gov) - Jun 17, 2012
P2, N=183, Completed, Sponsor: University of California, Davis
N=140 --> 183 Not yet recruiting --> Completed
- | New P4 trial: A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa (clinicaltrials.gov) - Jun 12, 2012
P4, N=18, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- ||| BMS-981164 / BMS
New P1 trial: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Jun 6, 2012
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
- | Trial completion: Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults (clinicaltrials.gov) - May 28, 2012
P2, N=17, Completed, Sponsor: Oculus Innovative Sciences, Inc.
Not yet recruiting --> Completed Recruiting --> Completed
- REGN846 / Regeneron
New P1/2 trial: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) - May 23, 2012
P1/2, N=19, Terminated, Sponsor: Regeneron Pharmaceuticals
- ||||| Eucrisa (crisaborole) / Pfizer
New P2 trial: Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis (clinicaltrials.gov) - May 17, 2012
P2, N=86, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
- | JNJ-39758979 / J&J
Trial termination: A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - May 15, 2012
P2, N=88, Terminated, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed Recruiting --> Terminated; This study was terminated prematurely due to 2 cases of agranulocytosis.
- Trial withdrawal: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
Recruiting --> Terminated; This study was terminated prematurely due to 2 cases of agranulocytosis. Not yet recruiting --> Withdrawn
- Enrollment change: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
Not yet recruiting --> Withdrawn N=10 --> 0
- |||| tacrolimus topical / Generic mfg.
Trial completion: Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis (clinicaltrials.gov) - May 14, 2012
P2, N=159, Completed, Sponsor: BioCis Pharma Ltd
N=10 --> 0 Active, not recruiting --> Completed
- | New P2 trial, IO biomarker: 2ndDermisII: Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis (clinicaltrials.gov) - May 10, 2012
P2, N=100, Active, not recruiting, Sponsor: Universidade do Porto
- | Ilaris (canakinumab) / Novartis
Enrollment closed: Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). (clinicaltrials.gov) - May 6, 2012
P2, N=20, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Zoryve (roflumilast cream) / Arcutis
Enrollment change: A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM) (clinicaltrials.gov) - May 3, 2012
P2, N=0, Withdrawn, Sponsor: Nycomed
Recruiting --> Active, not recruiting N=40 --> 0
- Ilaris (canakinumab) / Novartis
Trial completion: Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever (clinicaltrials.gov) - Apr 26, 2012
P2, N=10, Completed, Sponsor: Novartis Pharmaceuticals
N=40 --> 0 Recruiting --> Completed
- Enrollment open: Inhibitory Receptors in Eosinophils of Atopic Subjects (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=40, Recruiting, Sponsor: Meir Medical Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Ilaris (canakinumab) / Novartis
New P3 trial: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Apr 10, 2012
P3, N=15, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Trial completion: 0405-01-04: Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis (clinicaltrials.gov) - Apr 8, 2012
P2, N=114, Completed, Sponsor: Fougera Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=18, Completed, Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine
Recruiting --> Completed N=38 --> 18
- Trial completion: Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=18, Completed, Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine
N=38 --> 18 Enrolling by invitation --> Completed